相关实验视频
Updated: Jun 19, 2026
18:25
Orthotopic Liver Transplantation in Rats
Published on: July 1, 2012
29.9K
肝脏移植用于胆固醇性肝脏疾病:时间和疾病复发
Guilherme Grossi Lopes Cançado1,2, Maya Deeb3, Aliya F Gulamhusein1
1Division of Gastroenterology and Hepatology, Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
Hepatology (Baltimore, Md.)
|February 17, 2025
概括
原发性胆道胆炎 (PBC) 和原发性硬化胆炎 (PSC) 患者在肝移植 (LT) 中面临着独特的挑战. 定制的移植周护理对于优化这些罕见肝病的治疗结果和生存至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 移植手术 移植手术
- 胃肠病学 胃肠病学
背景情况:
- 原发性胆道胆炎 (PBC) 和原发性硬化胆炎 (PSC) 是肝移植 (LT) 的罕见原因,在北美和欧洲占8% - 14%.
- 这些情况在移植前期带来了独特的挑战,影响了患者的治疗和结果.
研究的目的:
- 审查患有PBC和PSC的患者的移植前期的旅程.
- 突出LT接入,疾病复发和移植后管理方面的挑战.
- 强调需要针对这些患者量身定制的方法.
主要方法:
- 在肝移植的背景下,对PBC和PSC的当前文献的综述.
- 分析与这些疾病的MELD得分限制相关的挑战.
- 讨论移植后的结果,复发和管理策略.
主要成果:
- MELD得分不充分反映了疾病特异性并发症,导致LT访问的潜在不平等.
- 病情复发后LT影响15% - 35%的患者在5 - 10年内,随着时间的推移,病情的复发率会增加.
- 乌尔索西胆酸在PBC的LT后是有益的,但对于复发PSC没有有效的治疗方法;炎症性肠病控制对复发PSC至关重要.
结论:
- 患有PBC和PSC的患者需要在整个LT旅程中采用独特的量身定制方法,从列表到移植后的护理.
- 解决MELD得分的局限性和专注于疾病复发和可修改的风险因素,如炎症性肠病是必不可少的.
- 优化结果和长期生存需要针对这些罕见的肝病进行专门的管理策略.
相关概念视频
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:28Kidney Transplant I: Introduction
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
01:26Kidney Transplant II: Surgical Procedure
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...